Occurence of adverse events due to continuous glucose monitoring.

Tereza Jadviscokova, Zuzana Fajkusova, Maria Pallayova, Jiri Luza, Galina Kuzmina

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

AIMS: Continuous glucose monitoring (CGM) using transcutaneous sensors is becoming a sophisticated method to control and regulate glucose metabolism. The transcutaneous sensor of the CGM system (CGMS Medtronic Minimed, Northridge, CA, USA) is chosen to measure glucose concentration in interstitial fluid up to three days after insertion even though its function remains stable for a longer period. The question arises, which factors really limit the period of sensor insertion without unnecessary risk. The aim of this study was to assess any adverse events occurring in the course of 9 days after the sensor insertion. METHODS: In a group of 22 healthy volunteers aged 21.8+/-1.30 y (mean +/- SE) a total of 26 sensors was inserted subcutaneously in gluteal or lumbar region for 9 days. Before insertion the site was sprayed with an antiseptic (Cutasept F, Bode Chemie, Hamburg, Germany). Local adverse reactions and disturbances in general condition were examined. RESULTS: In the course of 184 sensor-days, there were only minor local adverse events: hypersensitivity, itching, pain, redness, burning, subcutaneous hemorrhage. Additionally, sleep disturbances, attention deficits, problems related to the CGMS monitor, to adhesive tape and/or sensor were found. None of these resulted in sensor withdrawal. In 12 volunteers (55 %) no complications were observed. The sensor function measured according to electrical signals (ISIG) failed (always on day 1-2) in 4 cases (16 %). CONCLUSIONS: The present FDA approved 3-day insertion period for Medtronic transcutaneous sensor does not seem to limit its use and appears to be worth a careful revision.

Original languageEnglish
Pages (from-to)263-266
Number of pages4
JournalBiomedical papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia
Volume151
Issue number2
Publication statusPublished - Dec 2007
Externally publishedYes

Fingerprint

Glucose
Monitoring
Sensors
Lumbosacral Region
Buttocks
Local Anti-Infective Agents
Extracellular Fluid
Pruritus
Adhesives
Germany
Volunteers
Healthy Volunteers
Sleep
Hypersensitivity
Hemorrhage
Pain
Metabolism
Tapes
Fluids

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Occurence of adverse events due to continuous glucose monitoring. / Jadviscokova, Tereza; Fajkusova, Zuzana; Pallayova, Maria; Luza, Jiri; Kuzmina, Galina.

In: Biomedical papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia, Vol. 151, No. 2, 12.2007, p. 263-266.

Research output: Contribution to journalArticle

Jadviscokova, Tereza ; Fajkusova, Zuzana ; Pallayova, Maria ; Luza, Jiri ; Kuzmina, Galina. / Occurence of adverse events due to continuous glucose monitoring. In: Biomedical papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia. 2007 ; Vol. 151, No. 2. pp. 263-266.
@article{8a3b697919c24e2186980a2455a7a72d,
title = "Occurence of adverse events due to continuous glucose monitoring.",
abstract = "AIMS: Continuous glucose monitoring (CGM) using transcutaneous sensors is becoming a sophisticated method to control and regulate glucose metabolism. The transcutaneous sensor of the CGM system (CGMS Medtronic Minimed, Northridge, CA, USA) is chosen to measure glucose concentration in interstitial fluid up to three days after insertion even though its function remains stable for a longer period. The question arises, which factors really limit the period of sensor insertion without unnecessary risk. The aim of this study was to assess any adverse events occurring in the course of 9 days after the sensor insertion. METHODS: In a group of 22 healthy volunteers aged 21.8+/-1.30 y (mean +/- SE) a total of 26 sensors was inserted subcutaneously in gluteal or lumbar region for 9 days. Before insertion the site was sprayed with an antiseptic (Cutasept F, Bode Chemie, Hamburg, Germany). Local adverse reactions and disturbances in general condition were examined. RESULTS: In the course of 184 sensor-days, there were only minor local adverse events: hypersensitivity, itching, pain, redness, burning, subcutaneous hemorrhage. Additionally, sleep disturbances, attention deficits, problems related to the CGMS monitor, to adhesive tape and/or sensor were found. None of these resulted in sensor withdrawal. In 12 volunteers (55 {\%}) no complications were observed. The sensor function measured according to electrical signals (ISIG) failed (always on day 1-2) in 4 cases (16 {\%}). CONCLUSIONS: The present FDA approved 3-day insertion period for Medtronic transcutaneous sensor does not seem to limit its use and appears to be worth a careful revision.",
author = "Tereza Jadviscokova and Zuzana Fajkusova and Maria Pallayova and Jiri Luza and Galina Kuzmina",
year = "2007",
month = "12",
language = "English",
volume = "151",
pages = "263--266",
journal = "Biomedical papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia",
issn = "1213-8118",
publisher = "Palacky University",
number = "2",

}

TY - JOUR

T1 - Occurence of adverse events due to continuous glucose monitoring.

AU - Jadviscokova, Tereza

AU - Fajkusova, Zuzana

AU - Pallayova, Maria

AU - Luza, Jiri

AU - Kuzmina, Galina

PY - 2007/12

Y1 - 2007/12

N2 - AIMS: Continuous glucose monitoring (CGM) using transcutaneous sensors is becoming a sophisticated method to control and regulate glucose metabolism. The transcutaneous sensor of the CGM system (CGMS Medtronic Minimed, Northridge, CA, USA) is chosen to measure glucose concentration in interstitial fluid up to three days after insertion even though its function remains stable for a longer period. The question arises, which factors really limit the period of sensor insertion without unnecessary risk. The aim of this study was to assess any adverse events occurring in the course of 9 days after the sensor insertion. METHODS: In a group of 22 healthy volunteers aged 21.8+/-1.30 y (mean +/- SE) a total of 26 sensors was inserted subcutaneously in gluteal or lumbar region for 9 days. Before insertion the site was sprayed with an antiseptic (Cutasept F, Bode Chemie, Hamburg, Germany). Local adverse reactions and disturbances in general condition were examined. RESULTS: In the course of 184 sensor-days, there were only minor local adverse events: hypersensitivity, itching, pain, redness, burning, subcutaneous hemorrhage. Additionally, sleep disturbances, attention deficits, problems related to the CGMS monitor, to adhesive tape and/or sensor were found. None of these resulted in sensor withdrawal. In 12 volunteers (55 %) no complications were observed. The sensor function measured according to electrical signals (ISIG) failed (always on day 1-2) in 4 cases (16 %). CONCLUSIONS: The present FDA approved 3-day insertion period for Medtronic transcutaneous sensor does not seem to limit its use and appears to be worth a careful revision.

AB - AIMS: Continuous glucose monitoring (CGM) using transcutaneous sensors is becoming a sophisticated method to control and regulate glucose metabolism. The transcutaneous sensor of the CGM system (CGMS Medtronic Minimed, Northridge, CA, USA) is chosen to measure glucose concentration in interstitial fluid up to three days after insertion even though its function remains stable for a longer period. The question arises, which factors really limit the period of sensor insertion without unnecessary risk. The aim of this study was to assess any adverse events occurring in the course of 9 days after the sensor insertion. METHODS: In a group of 22 healthy volunteers aged 21.8+/-1.30 y (mean +/- SE) a total of 26 sensors was inserted subcutaneously in gluteal or lumbar region for 9 days. Before insertion the site was sprayed with an antiseptic (Cutasept F, Bode Chemie, Hamburg, Germany). Local adverse reactions and disturbances in general condition were examined. RESULTS: In the course of 184 sensor-days, there were only minor local adverse events: hypersensitivity, itching, pain, redness, burning, subcutaneous hemorrhage. Additionally, sleep disturbances, attention deficits, problems related to the CGMS monitor, to adhesive tape and/or sensor were found. None of these resulted in sensor withdrawal. In 12 volunteers (55 %) no complications were observed. The sensor function measured according to electrical signals (ISIG) failed (always on day 1-2) in 4 cases (16 %). CONCLUSIONS: The present FDA approved 3-day insertion period for Medtronic transcutaneous sensor does not seem to limit its use and appears to be worth a careful revision.

UR - http://www.scopus.com/inward/record.url?scp=58149187302&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58149187302&partnerID=8YFLogxK

M3 - Article

VL - 151

SP - 263

EP - 266

JO - Biomedical papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia

JF - Biomedical papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia

SN - 1213-8118

IS - 2

ER -